-
Audit Yourself to Get More From GenAI
Carolyn Geason-Beissel/MIT SMR | Getty Images More than a year into using generative AI daily, I wondered whether I was getting the most out of my AI use. There was no benchmark or feedback loop, and no one was grading my sessions with ChatGPT and Claude — until I created a self-audit. I did what… →
-
Effect of multicomponent exercise intervention on multidimensional frailty in older adults with mild cognitive impairment: a secondary analysis of the MIND-STEP randomised clinical trial
BACKGROUND: Frailty is common among older adults with mild cognitive impairment (MCI) and encompasses physical, cognitive, psychological and social domains, yet randomised evidence on theory-informed multicomponent exercise interventions targeting multidimensional frailty remains limited. This secondary analysis of the MIND-STEP RCT evaluated intervention effects across frailty domains. →
-
Adjuvant administration probiotic effects on sexual function in depressant men undergoing selective serotonin reuptake inhibitor treatment: a double-blinded randomized controlled trial
CONCLUSION: Adding Lactofem to Escitalopram treatment significantly reduces depression severity and enhances sexual function in men with mild to moderate depression. →
-
Combined Low-Level Laser and Ultrasound Therapy for Growing Pains in Children Aged Four to Twelve Years: A Pilot Study
Growing pains are a frequent form of musculoskeletal pain in children, with an uncertain etiology and currently limited therapeutic options. Considering the need for non-pharmacological approaches, the potential of low-level laser therapy combined with ultrasonic therapy stands out as a possible therapeutic technique for this condition. The objective of this study was to analyze the… →
-
Diabetes Management by Ayurvedic Practitioners Using a Clinical Guideline Versus Usual Practice: A Feasibility Cluster Randomized Trial in Nepal
CONCLUSION: This feasibility trial demonstrated successful recruitment, follow-up, and intervention adherence. A definitive trial is feasible to evaluate the intervention’s effectiveness in T2DM management. →
-
Leaders at All Levels: How Argenx Scaled to $4 Billion Without Bureaucracy
Biotech companies face the same dilemma as businesses in other industries: Innovation drops off dramatically with scale. European biotech Argenx has reached a market value of more than $40 billion, having so far escaped that innovation trap. How has it done this? The company shuns hierarchy and instead organizes into small teams, each dedicated to… →
-
Okta’s CRO: From $850M in Losses to $760M Profit (The AI Agent Bet) | Jon Addison
The GTM Podcast is available on any major directory, including: Apple Podcasts Spotify YouTube Okta’s CRO Jon Addison joins GTMnow host Sophie to break down the full story behind Okta’s remarkable revenue turnaround, the launch of Okta for AI Agents, and the go-to-market playbook that’s carrying them from $3B toward a $5B ARR target. From nearly $850M… →
-
Streamlining Inherited Cancer Identification via an EMR-Integrated Risk Assessment Platform: A Nonrandomized Clinical Trial
CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, almost one-third of the population met national genetic counseling criteria for an inherited cancer syndrome, highlighting a substantial gap in usual care identification. Integrating patient-facing FHH collection and assessment tools for primary care patients improves inherited cancer risk identification and highlights opportunities to further enhance both risk… →
-
Development of an intervention theory for a mobile mammography unit research project for breast cancer screening
SETTING: In France, participation rates in breast cancer screening have been decreasing, along with socio-territorial inequalities. To enhance women’s access to breast cancer screening, an interventional research project was implemented to assess the effectiveness, efficiency, and optimal modalities of a mobile mammography unit for women living remotely in Normandy. →
-
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug-Metabolizing Enzymes
Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan-genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time-dependent inhibitor of CYP3A4. These results prompted further evaluation in… →
